39: The Year 2020 in Review with Sukh Nijjer
In the first Parallax episode of 2021, Ankur welcomed back Sukh Nijjer from Imperial College London to review the most impactful events and advances in cardiology from 2020.
In the first part of the episode, Ankur and Sukh focus on the mechanism of the coronavirus and its effects on the heart including clotting abnormality and troponin elevation. They discuss their clinical experiences and observations within the UK and US settings in light of the latest data. Sukh offers practical tips on how to approach patient management during this pandemic.
Following this, Ankur and Sukh analyse the controversial STRENGHT study in light of the results from REDUCE-IT. They discuss the different attitudes toward early cryoablation therapy in the context of STOP AF and EARLY-AF studies. Sukh reviews the findings of the RHAPSODY Phase 3 trial and the revolution of SGLT2 inhibitors in the treatment of heart failure.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Sponsored by Edwards.
Read MoreRead Less
All Episodes
Mallory was not prepared when she underwent her first heart surgery in seventh grade: She was hoping to regain her stamina, instead she experienced what she describes as a loss of self. Mallory was born with a rare heart disease called a Ebstein’s anomaly.
Read More
How does Dr Mehra think about building opportunities? What were his formative experiences? How does he think about the role of mentorship in medicine? What is Dr Mehra’s message to our listeners?Dr Mehra does not frame his experiences as failures or successes; he looks at all events with one question in mind: What can I learn from this?
In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
Read More
In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
In the first Parallax episode of 2021, Ankur welcomed back Sukh Nijjer from Imperial College London to review the most impactful events and advances in cardiology from 2020.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
Read More
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
In the Season 2 finale, Ankur Kalra is joined by the legendary Martin B Leon, Professor at Columbia University, director of the TCT and chairman emeritus of the CRF.
What makes Dr Martin B Leon tick? What is his message to cardiologists and/or researchers at the beginning of their careers? How did the pandemic and his work as a clinician in New York change his perspective?
Read More
What makes Dr Martin B Leon tick? What is his message to cardiologists and/or researchers at the beginning of their careers? How did the pandemic and his work as a clinician in New York change his perspective?
This week Parallax welcomed its first non-physician/researcher guest: health advocate Lindsay Davis. Lindsay, ballerina with ambitions to study at Julliard, was experiencing the symptoms of hypertrophic cardiomyopathy (HCM) from her early teens, but she had not been diagnosed until she was 17.
In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.
Read More
In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.
In 2020, women still only represent 16% of editorial boards.
US Cardiology Review journal, has recently seen a 7-fold increase in female editorial board members in response to journal-based strategic initiatives and the stellar work of USC editorial board leadership, Ankur Kalra (Editor in Chief) and Bill Gogas (Deputy Editor in Chief), who were keen to drive this change. With thanks to Dr Anastasia Mihailidou’s tenure as a new board member and her suggested nominees, ten new female board members have recently joined US Cardiology Review’s editorial board.
Read More
US Cardiology Review journal, has recently seen a 7-fold increase in female editorial board members in response to journal-based strategic initiatives and the stellar work of USC editorial board leadership, Ankur Kalra (Editor in Chief) and Bill Gogas (Deputy Editor in Chief), who were keen to drive this change. With thanks to Dr Anastasia Mihailidou’s tenure as a new board member and her suggested nominees, ten new female board members have recently joined US Cardiology Review’s editorial board.
One of the first things painted by the young Mike Gibson, today Professor of Medicine at Harvard, researcher and interventional cardiologist, was a cloud. Years later while painting angiograms Dr Gibson came up with the idea of myocardial blush: The blush was that cloud of dye in the heart muscle.
In this episode, Mike opens up about his childhood in Stilwell, Oklahoma. Ankur and Mike discuss how the inductive quality of art can complement the deductive principles of science. Mike recalls earlier stages of his career and warns about the blinding effect of the ego-driven, competitive culture of cardiology. Ankur asks Mike about fatherhood and about his role as an educator.
What does it mean to be fearless as a medical professional? How can you protect yourself from the emotional toll of the profession? What is Mike’s advice to early career cardiologists?
Sponsored by Edwards.
Read More
In this episode, Mike opens up about his childhood in Stilwell, Oklahoma. Ankur and Mike discuss how the inductive quality of art can complement the deductive principles of science. Mike recalls earlier stages of his career and warns about the blinding effect of the ego-driven, competitive culture of cardiology. Ankur asks Mike about fatherhood and about his role as an educator.
What does it mean to be fearless as a medical professional? How can you protect yourself from the emotional toll of the profession? What is Mike’s advice to early career cardiologists?
Sponsored by Edwards.
In this week’s episode Ankur Kalra asks Dr Suzanne J Baron, Director of Interventional Cardiovascular Research at Lahey Hospital & Medical Center: How do we measure the value of a novel technology?
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Read More
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Read More
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
This week Parallax welcomed its first non-physician/researcher guest: health advocate Lindsay Davis. Lindsay, ballerina with ambitions to study at Julliard, was experiencing the symptoms of hypertrophic cardiomyopathy (HCM) from her early teens, but she had not been diagnosed until she was 17.
In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.
Read More
In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.
In 2020, women still only represent 16% of editorial boards.
US Cardiology Review journal, has recently seen a 7-fold increase in female editorial board members in response to journal-based strategic initiatives and the stellar work of USC editorial board leadership, Ankur Kalra (Editor in Chief) and Bill Gogas (Deputy Editor in Chief), who were keen to drive this change. With thanks to Dr Anastasia Mihailidou’s tenure as a new board member and her suggested nominees, ten new female board members have recently joined US Cardiology Review’s editorial board.
Read More
US Cardiology Review journal, has recently seen a 7-fold increase in female editorial board members in response to journal-based strategic initiatives and the stellar work of USC editorial board leadership, Ankur Kalra (Editor in Chief) and Bill Gogas (Deputy Editor in Chief), who were keen to drive this change. With thanks to Dr Anastasia Mihailidou’s tenure as a new board member and her suggested nominees, ten new female board members have recently joined US Cardiology Review’s editorial board.
One of the first things painted by the young Mike Gibson, today Professor of Medicine at Harvard, researcher and interventional cardiologist, was a cloud. Years later while painting angiograms Dr Gibson came up with the idea of myocardial blush: The blush was that cloud of dye in the heart muscle.
In this episode, Mike opens up about his childhood in Stilwell, Oklahoma. Ankur and Mike discuss how the inductive quality of art can complement the deductive principles of science. Mike recalls earlier stages of his career and warns about the blinding effect of the ego-driven, competitive culture of cardiology. Ankur asks Mike about fatherhood and about his role as an educator.
What does it mean to be fearless as a medical professional? How can you protect yourself from the emotional toll of the profession? What is Mike’s advice to early career cardiologists?
Sponsored by Edwards.
Read More
In this episode, Mike opens up about his childhood in Stilwell, Oklahoma. Ankur and Mike discuss how the inductive quality of art can complement the deductive principles of science. Mike recalls earlier stages of his career and warns about the blinding effect of the ego-driven, competitive culture of cardiology. Ankur asks Mike about fatherhood and about his role as an educator.
What does it mean to be fearless as a medical professional? How can you protect yourself from the emotional toll of the profession? What is Mike’s advice to early career cardiologists?
Sponsored by Edwards.
In this week’s episode Ankur Kalra asks Dr Suzanne J Baron, Director of Interventional Cardiovascular Research at Lahey Hospital & Medical Center: How do we measure the value of a novel technology?
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Read More
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Read More
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?